Determination of Regulatory Review Period for Purposes of Patent Extension; ALYFTREK
Health and Human Services Department, Food and Drug Administration
About this archived opportunity
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ALYFTREK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.
Historical details
- Status
- Closed
- Deadline
- April 14, 2026
- First captured
- February 14, 2026
- Publisher reference
- 2026-02968
Eligibility: Business
This opportunity has closed
Determination of Regulatory Review Period for Purposes of Patent Extension; ALYFTREK
by Health and Human Services Department, Food and Drug Administration
Get notified when similar opportunities open
We'll save this search and email you when new determination, regulatory, review opportunities are posted. Free.